Search
Ezetimibe
go.drugbank.com/drugs/DB00973ApprovedInvestigationalEzetimibe is a lipid-lowering compound that inhibits intestinal cholesterol and phytosterol absorption. The discovery and research of this drug began in the early 1990s, after the intravenous administration of radiolabelled ezetimibe in ...
Categories: Hypolipidemic Agents Indicated for Hyperlipidemia, Non-statin Hypolipidemic Agents Indicated for HyperlipidemiaRESP301
go.drugbank.com/drugs/DB16497InvestigationalRESP301 was under investigation in clinical trials for various conditions. … Additionally, RESP301 was investigated in a withdrawn trial (NCT04842331) for preventing viral exposure and transmission of COVID-19 and in a not yet recruiting trial (NCT04386070) for preventing pulmonary
Categories: Experimental Unapproved Treatments for COVID-19Cantharidin
go.drugbank.com/drugs/DB12328ApprovedInvestigational[A32891, A32892] For its natural purpose, the male blister beetle secretes and presents the cantharidin to a female beetle as a copulatory gift during mating. … Available synthetically since the 1950s, topical applications of cantharidin have been used predominantly as a treatment for cutaneous warts since that time.
Pravastatin
go.drugbank.com/drugs/DB00175ApprovedInvestigationalPravastatin is the 6-alpha-hydroxy acid form of mevastatin. Pravastatin was firstly approved in 1991 becoming the second available statin in the United States. It was the first statin administered as the active form and not as a prodrug....
Categories: Hypolipidemic Agents Indicated for HyperlipidemiaMiglitol
go.drugbank.com/drugs/DB00491ApprovedMiglitol inhibits alpha-glucosidase, making less sugars available for digestion and reducing postprandial hyperglycemia. … Miglitol should be taken at the start of a meal for maximal effect and the effect will depend on the amount of poly and oligosaccharides in the diet.
Garadacimab
go.drugbank.com/drugs/DB15629Approved[A273993,A273998] As opposed to [lanadelumab], another prophylactic agent for HAE that targets kallikrein, garadacimab targets activated factor XII, the first factor in the contact system responsible for … [A273993] In June 2025, garadacimab was approved by the US FDA for the prophylaxis of HAE episodes in patients ≥12 years of age.
Interferon gamma-1b
go.drugbank.com/drugs/DB00033ApprovedInvestigationalThe sequence displayed is a cDNA sequence which codes for human interferon gamma, as described by Gray et. al. and not specifically interferon gamma 1b. … Production of Actimmune is achieved by fermentation of a genetically engineered Escherichia coli bacterium containing the DNA which encodes for the human protein.
Enpatoran
go.drugbank.com/drugs/DB16501InvestigationalEnpatoran (M5049) was under investigation in clinical trials for various conditions. … Additionally, M5049 was studied for COVID-19 pneumonia in a completed trial with results (NCT04448756) and is currently being recruited for a trial involving participants with dermatomyositis and polymyositis
Categories: Experimental Unapproved Treatments for COVID-19Neuropeptide Y
go.drugbank.com/drugs/DB11788ApprovedInvestigationalWithdrawnNeuropeptide Y is under investigation for the basic science of Type 2 Diabetes Mellitus.
Domperidone
go.drugbank.com/drugs/DB01184ApprovedInvestigationalVet approvedA specific blocker of dopamine receptors. It speeds gastrointestinal peristalsis, causes prolactin release, and is used as antiemetic and tool in the study of dopaminergic mechanisms.
Categories: Drugs for Functional Gastrointestinal Disorders